Elisabetta Leo
Senior Director, Early Development Asset Lead AstraZeneca
Seminars
Wednesday 25th February 2026
Navigating Risk & Development Strategy to Bring Novel & First-in-Class ADCs to the Clinic
12:30 pm
- Emphasising the importance of pursuing novel targets amongst a crowded clinical landscape to develop ADCs with meaningful patient impact
- Contextualising learnings from advancing a novel target ADC to clinical trials
- Incorporating learnings from historical profiles of adjacent target ADC:
- What are the indications of promising performance?
